X

Trial Profile

A Phase 1/2 Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NC-318 (Primary) ; Carboplatin; Docetaxel; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer
Focus Adverse reactions
Sponsors NextCure

Most Recent Events

11 Aug 2021 Planned initiation date changed from 6 Sep 2020 to 6 Dec 2021.
11 Aug 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
22 Jul 2020 Study design changed from Single Group Assignment to Parallel Assignment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com